

University of Groningen

Catalytic asymmetric synthesis of chromenes and tetrahydroquinolines via sequential allylic alkylation and intramolecular Heck coupling

Hornillos, Valentin; van Zijl, Anthoni W.; Feringa, B.L.

Published in:
Chemical Communications

DOI:
[10.1039/c2cc30395g](https://doi.org/10.1039/c2cc30395g)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2012

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Hornillos, V., van Zijl, A. W., & Feringa, B. L. (2012). Catalytic asymmetric synthesis of chromenes and tetrahydroquinolines via sequential allylic alkylation and intramolecular Heck coupling. *Chemical Communications*, 48(31), 3712-3714. DOI: 10.1039/c2cc30395g

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

ELECTRONIC SUPPLEMENTARY INFORMATION

Catalytic Asymmetric Synthesis of Chromenes and tetrahydroquinolines via Sequential Allylic Alkylation and Intramolecular Heck Coupling

Valentín Hornillos, Anthoni W. van Zijl and Ben L. Feringa*

*Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG, Groningen,
The Netherlands*


Table of Contents	S2
General procedures	S3
Synthesis of Allylic bromides 1 and 2	S3
General procedure A: Enantioselective Cu-catalyzed AAA	S4
General procedure B: Intramolecular Heck reaction	S9
General procedure C: RCM of compounds 4c, 6c and 5d	S14
Stereoselective hydroboration-oxidation	S15
Stereoselective hydrogenation	S16
NMR spectra	S18
Selected IR spectra	S46

General procedures:


^1H NMR and ^{13}C NMR spectra were recorded on a Varian AMX400 (400 and 100 MHz, respectively), a Varian VXR300 (300 and 75 MHz, respectively), or a Varian VXR200 NMR spectrometer (200 MHz and 75 MHz, respectively) with CDCl_3 as solvent. Chemical shifts were determined relative to the residual solvent peaks (CHCl_3 , $\delta = 7.26$ ppm for ^1H NMR, $\delta = 77.0$ ppm for ^{13}C NMR). The following abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Carbon assignments are based on APT ^{13}C -NMR experiments. Enantiomeric excesses were determined by chiral HPLC using a Shimadzu LC-10ADVP HPLC equipped with a Shimadzu SPD-M10AVP diode array detector or by capillary GC analysis (HP 6890, CP-Chiralsil-Dex-CB column (25 m x 0.25 mm) or Chiraldex B-PM (30 m x 0.25 mm x 0.25 μm)) using a flame ionization detector, in comparison with racemic products. Racemic products were obtained by the same procedure as the enantioselective allylic alkylation only using $\text{CuBr}\cdot\text{SMe}_2$ (10 mol%), PPh_3 (20 mol%) and the corresponding Grignard reagent (1.70 eq.) at -80 °C in CH_2Cl_2 . The ratio of regioisomers branch/linear (AAA) and exocyclic/endocyclic ratio (Heck coupling) were determined by ^1H NMR. Optical rotations were measured on a *Schmidt + Haensch* polarimeter (Polartronic MH8) with a 10 cm cell (c given in g/100 mL) at 20 °C. Thin-layer chromatography (TLC) was performed on Merck TLC Silica gel 60 Kieselguhr F₂₅₄. Flash chromatography was performed on silica gel Merck Type 9385 230-400 mesh. Mass spectra were recorded on a AEI-MS-902 mass spectrometer (EI+) or an LTQ Orbitrap XL (ESI+).

All reactions were carried out under a nitrogen atmosphere using oven dried glassware and using standard Schlenk techniques. CH_2Cl_2 was dried and distilled over calcium hydride. $\text{CuBr}\cdot\text{SMe}_2$, Hoveyda-Grubbs 2nd generation catalysts, Wilkinson catalysts, (*R,R*)-Taniaphos and commercially available reagents were purchased from Aldrich, and used without further purification. Grignard reagents were purchased from Aldrich (MeMgBr, EtMgBr) or prepared from the corresponding alkyl bromides and magnesium turnings in Et_2O following standard procedures. Grignard reagents were titrated using *s*-BuOH and catalytic amounts of 1,10-phenanthroline.

Synthesis of Allylic bromides 1 and 2




(*E*)-2-(4-Bromobut-2-enyloxy)-1-bromobenzene (1)



A suspension of *o*-bromophenol (10 mmol, 1.16 mL), 1,4-dibromobut-2-ene (40 mmol, 8.6 g) and K_2CO_3 (15 mmol, 2.05 g) in CH_3CN (100 mL) was heated at reflux temperature for 7 h. The reaction mixture was then concentrated and H_2O (100 mL) and Et_2O (100 mL) were added. The


aqueous layer was separated and extracted with Et₂O (50 mL). The combined organic layer were dried (MgSO₄), filtered and concentrated in vacuo. Purification of the residue by flash chromatography (SiO₂, Et₂O/*n*-pentane gradient (1:99 to 5:95), R_f = 0.4) afforded **1** (2.9 g, 95% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.54 (dd, *J* = 7.8 and 1.6 Hz, 1H), 7.27-7.23 (m, 1H), 6.88-6.83 (m, 2H), 6.15 (m, 1H), 6.01 (m, 1H), 4.58 (d, *J* = 4.9 Hz, 2H), 4.00 (d, *J* = 7.4 Hz, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 154.7, 133.5, 129.4, 129.2, 128.4, 122.2, 113.6, 112.4, 68.2, 31.6. HRMS (EI, *m/z*): calcd for C₁₀H₁₀Br₂O⁺: 307.9058; found: 307.9064.

(*E*)-*N*-(4-Bromobut-2-enyl)-*N*-(2-bromophenyl)-4-methylbenzenesulfonamide (**2**)



Prepared from *o*-bromophenyltosylamide (7.36 mmol, 2.4 g) following the procedure described for **1** (Reaction time = 16 h). Purification by column chromatography (SiO₂, Et₂O/*n*-pentane gradient (5:95 to 15:85), R_f = 0.4) afforded **2** (2.52 g, 75% yield) as a white solid, mp 90-91 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, *J* = 8.2 Hz, 2H), 7.59 (d, *J* = 8.2 Hz, 1H), 7.30-7.24 (m, 3H), 7.21-7.16 (m, 1H), 7.11 (d, *J* = 7.9 Hz, 1H), 5.81-5.75 (m, 1H), 5.68-5.60 (m, 1H), 4.18 (m, 2H), 3.80 (d, *J* = 7.8 Hz, 2H), 2.44 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.7, 137.5, 136.7, 133.9, 132.6, 131.0, 129.9, 129.5, 129.3, 127.9, 127.8, 125.6, 52.2, 31.2, 21.6. HRMS (EI, *m/z*): calcd for C₁₇H₁₇Br₂NO₂S⁺: 458.9326; found: 458.9337.


General procedure A: Enantioselective Cu-catalyzed synthesis of compounds **3** and **4**



In a dry Schlenk tube equipped with septum and stirring bar, CuBr·SMe₂ (0.01 mmol, 2.05 mg, 5.0 mol%) and (*R,R*)-Taniaphos (**L1**) (0.012 mmol, 8.25 mg, 6 mol%) were dissolved in CH₂Cl₂ (2.0 mL) and stirred under nitrogen atmosphere at room temperature for 20 min. The mixture was cooled to -80 °C and a solution of Grignard reagent (solution in Et₂O, 1.7 eq.) in CH₂Cl₂ (1.0 mL) was added dropwise over 30 min via a syringe pump. Subsequently, a solution of allylic bromide **1** or **2** (0.2 mmol) in CH₂Cl₂ (1.0 mL) was added dropwise over 1 h via syringe pump. Once the addition was complete, the resulting mixture was stirred at -80 °C for 16h. The reaction was quenched by addition of MeOH (2.0 mL) and the mixture was allowed to warm up to rt. Saturated aqueous NH₄Cl solution (2 mL) was added and the organic phase separated. The aqueous phase was extracted with CH₂Cl₂ (2 x 10 mL). The combined organic phases were dried over MgSO₄ and concentrated under reduced pressure to yield the crude product which was purified by flash chromatography (SiO₂, EtOAc/Pentane). In accordance with the results


obtained in our previous work, the absolute configuration of these compounds is assumed to be (*S*).¹

(+)-1-Bromo-2-(2methylbut-3-enyloxy)benzene (3a)




The title compound was prepared from **1** (3.0 mmol, 918 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.60) afforded **3a** (88% yield, 634 mg, 99% *ee*, [α]_D = +8.6 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined for Heck product **5a**. ¹H NMR (400 MHz, CDCl₃) δ 7.53 (dd, *J* = 7.8 and 1.6 Hz, 1H), 7.24 (m, 1H), 6.84 (m, 2H), 5.92 (m, 1H), 5.13 (m, 2H), 3.95 (dd, *J* = 8.9 and 6.0 Hz, 1H), 3.83 (dd, *J* = 8.9 and 7.0 Hz, 1H), 2.75 (m, 1H), 1.20 (d, *J* = 6.8 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.3, 140.1, 133.3, 128.3, 121.7, 114.9, 113.2, 112.3, 73.4, 37.4, 16.5. HRMS (EI, *m/z*): calcd for C₁₁H₁₃BrO⁺: 240.0150; found: 240.0136.

(+)-1-bromo-2-(2-ethylbut-3-enyloxy)benzene (3b)



The title compound was prepared from **1** (0.40 mmol, 120 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.7) afforded **3b** (97% yield, 97 mg, 99% *ee*, [α]_D²⁰ = +28.0 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OD-H (99.75% *n*-heptane/0.25% *i*-PrOH), 40 °C, retention times (min) 13.2 (major) and 13.7 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.24 (m, 1H), 6.87 (dd, *J* = 8.2 and 1.3 Hz, 1H), 6.82 (m, 1H), 5.80 (m, 1H), 5.16 (m, 2H), 3.90-3.99 (m, 2H), 2.49 (m, 1H), 1.75 (m, 1H), 1.48 (m, 1H), 0.96 (t, *J* = 7.5 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.4, 138.9, 133.3, 128.3, 121.6, 116.4, 113.2, 112.4, 72.0, 45.2, 24.0, 11.4 ppm. HRMS (APCI⁺, *m/z*): calculated for C₁₂H₁₆BrO [M+H⁺]: 255.0385, found: 255.0381.


(+)-1-bromo-2-(2-vinylhex-5-enyloxy)benzene (3c)



¹ F. López, A. W. van Zijl, A. J. Minnaard and B. L. Feringa, *Chem. Commun.*, 2006, 409.


The title compound was prepared from **1** (0.65 mmol, 200 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.8) afforded **3c** (86% yield, 157 mg, 96% *ee*, [α]_D²⁰ = +7.4 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OD-H (99.9 % *n*-heptane/0.1% *i*-PrOH, FL= 0.25 mL min⁻¹), 40 °C, retention times (min) 40.7 (major) and 43.1 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.24 (m, 1H), 6.87 (dd, *J* = 8.2 and 1.4 Hz, 1H), 6.82 (m, 1H), 5.81 (m, 2H), 5.17 (m, 2H), 5.00 (m, 2H), 4.00-3.90 (m, 2H), 2.60 (m, 1H), 2.18 (m, 1H), 2.10 (m, 1H), 1.81 (m, 1H), 1.57 (m, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.4, 138.8, 138.5, 133.3, 128.3, 121.7, 116.7, 114.7, 113.2, 112.4, 72.2, 43.0, 31.0, 30.2 ppm. HRMS (APCI+, *m/z*): calculated for C₁₄H₁₈BrO [M+H⁺]: 281.0541, found: 281.0536.

(+)-1-bromo-2-(2-vinylhept-6-enyloxy)benzene (3d)



The title compound was prepared from **1** (1.31 mmol, 400 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.8) afforded **3d** (90% yield, 348 mg, 95% *ee*, [α]_D²⁰ = +28.0 (*c* 1.2 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OD-H (99.9 % *n*-heptane/0.1% *i*-PrOH, FL= 0.25 mL min⁻¹), 40 °C, retention times (min) 40.0 (major) and 45.9 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.24 (m, 1H), 6.86 (dd, *J* = 8.3 and 1.3 Hz, 1H), 6.81 (m, 1H), 5.81 (m, 2H), 5.16 (m, 2H), 5.00 (m, 2H), 3.98-3.88 (m, 2H), 2.57 (m, 1H), 2.09 (m, 2H), 1.71 (m, 1H), 1.45 (m, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.4, 139.0, 138.7, 133.3, 128.3, 121.7, 116.4, 114.5, 113.2, 112.4, 72.3, 43.5, 33.8, 30.6, 26.2 ppm. HRMS (APCI+, *m/z*): calculated for C₁₅H₂₀BrO [M+H⁺]: 295.0698, found: 295.0692.


(+)-1-bromo-2-(2-vinyloct-7-enyloxy)benzene (3e)



The title compound was prepared from **1** (0.65 mmol, 200 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.8) afforded **3e** (94% yield, 190 mg, 97% *ee*, [α]_D²⁰ = +24.0 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OD-H (99.9 % *n*-heptane/0.1% *i*-PrOH, FL= 0.25


mL min⁻¹), 40 °C, retention times (min) 41.0 (major) and 44.0 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.24 (m, 1H), 6.87 (dd, *J* = 8.2 and 1.2 Hz, 1H), 6.82 (m, 1H), 5.81 (m, 2H), 5.15 (m, 2H), 4.95 (m, 2H), 3.98-3.88 (m, 2H), 2.56 (m, 1H), 2.07 (m, 2H), 1.71 (m, 1H), 1.45 (m, 5H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.4, 139.1, 139.0, 133.3, 128.3, 121.7, 116.4, 114.3, 113.1, 112.3, 72.3, 43.5, 33.7, 30.9, 28.9, 26.4 ppm. HRMS (APCI+, *m/z*): calculated for C₁₆H₂₂BrO [M+H⁺]: 309.0854, found: 309.0849.

(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-methylbut-3-enyl)benzenesulfonamide (4a)




The title compound was prepared from **2** (1.0 mmol, 459 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R*_f = 0.65) afforded **4a** (72% yield, 282 mg, 99% *ee*, [α]_D²⁰ = +1.6 (*c* 14.9 in CHCl₃)) as a white solid, mp 78-79 °C. Enantiomeric excess determined by chiral HPLC analysis, Chiralpak AD (99% *n*-heptane/1% *i*-PrOH), 40 °C, retention times (min) 19.3 (major) and 20.9 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.57 (m, 3H), 7.25 (m, 4H), 7.16 (m, 1H), 5.67 (m, 1H), 4.97 (m, 2H), 3.53 (m, 2H), 2.43 (s major peak, 3H), 2.42 (s minor peak, 3H), 2.34 (m, minor peak, 1H), 2.21 (m, major peak, 1H), 1.07 (d, *J* = 6.7 Hz, major peak, 3H), 1.02 (d, *J* = 6.8 Hz, minor peak, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.5, 143.4, 141.1, 140.9, 138.2, 136.7, 136.4, 134.1, 133.4, 132.4, 129.6, 129.5, 129.4, 128.0, 127.9, 127.8, 127.7, 125.5, 124.8, 114.8, 114.7, 56.5, 37.0, 21.6, 18.0 ppm. HRMS (ESI+, *m/z*): calculated for C₁₈H₂₁BrNO₂S [M+H⁺]: 394.0476, found: 394.0471.

(+)-*N*-(2-bromophenyl)-*N*-(2-ethylbut-3-enyl)-4-methylbenzenesulfonamide (4b)




The title compound was prepared from **2** (0.30 mmol, 140 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R*_f = 0.7) afforded **4b** (99% yield, 123 mg, 99% *ee*, [α]_D²⁰ = +26.0 (*c* 1.0 in CHCl₃)) as a waxy solid. Enantiomeric excess determined for Heck product **6b**. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (m, 3H), 7.28-7.11 (m, 5H), 5.55-5.39 (m, 1H), 5.01-4.86 (m, 2H), 3.65 (m, 1H), 3.48 (m, 1H), 2.41 (m, 3H), 2.13 (m, minor peak, 1H), 1.89 (m, major peak, 1H), 1.68 (m, major peak, 1H), 1.54 (m, minor peak, 1H), 1.20 (m, 1H), 0.82 (d, *J* = 7.3 Hz, minor peak, 3H), 0.78 (d, *J* = 7.4 Hz, major peak, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.4, 139.5, 139.4, 138.3, 138.0, 136.6, 136.5, 134.1, 134.0, 133.6, 132.5, 129.6, 129.5, 129.4, 127.9, 127.8, 127.7, 127.6, 125.5, 124.7, 116.8, 116.6, 55.4, 55.0, 45.3, 44.5, 25.0, 24.9, 21.6, 11.3, 11.2 ppm. HRMS (APCI+, *m/z*): calculated for C₁₉H₂₃BrNO₂S [M+H⁺]: 408.0633, found: 408.0638.

(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-vinylhex-5-enyl)benzenesulfonamide (4c)




The title compound was prepared from **2** (0.50 mmol, 230 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.7) afforded **4c** (87% yield, 187 mg, 96% *ee*, [α]_D²⁰ = +8.0 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralpak AD (99.5 % *n*-heptane/0.5% *i*-PrOH), 40 °C, retention times (min) 27.9 (major) and 31.6 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.60-7.53 (m, 3H), 7.28-7.13 (m, 5H), 5.77-5.67 (m, 1H), 5.57-5.39 (m, 1H), 5.02 (m, 1H), 4.96-4.86 (m, 3H), 3.65 (m, 1H), 3.48 (m, 1H), 2.42 (m, 3H), 2.26 (m, minor peak, 1H), 2.00 (m, major peak, 1H), 1.89 (m, 1H), 1.71 (m, 1H), 1.60 (m, 1H), 1.26 (m, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.4, 139.5, 139.4, 138.3, 138.0, 136.6, 136.5, 134.1, 134.0, 133.7, 132.6, 129.6, 129.5, 129.4, 127.9, 127.8, 127.7, 127.6, 125.4, 124.6, 117.1, 116.8, 114.7, 114.5, 55.5, 55.1, 43.1, 42.5, 31.2, 31.1, 31.0, 30.9, 21.6 ppm. HRMS (APCI+, *m/z*): calculated for C₂₁H₂₅BrNO₂S [M+H⁺]: 434.0789, found: 434.0784.

(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-vinylhept-6-enyl)benzenesulfonamide (4d)




The title compound was prepared from **2** (0.87 mmol, 400 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.7) afforded **4d** (86% yield, 234 mg, 95% *ee*, [α]_D²⁰ = +54.0 (*c* 1.9 in CHCl₃)) as a colorless oil. Enantiomeric excess determined for Heck product **6d**. ¹H NMR (400 MHz, CDCl₃) δ 7.59-7.53 (m, 3H), 7.29-7.13 (m, 5H), 5.80-5.68 (m, 1H), 5.57-5.39 (m, 1H), 5.01-4.87 (m, 4H), 3.65 (m, 1H), 3.48 (m, 1H), 2.42 (m, 3H), 2.25 (m, minor peak, 1H), 1.98 (m, major peak + CH₂, 3H), 1.63 (m, major peak, 1H), 1.50 (m, minor peak, 1H), 1.36 (m, 1H), 1.19 (m, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.5, 139.6, 138.7, 138.0, 136.5, 132.5, 127.9, 127.6, 125.4, 124.7, 116.8, 116.5, 114.5, 114.4, 55.7, 55.1, 43.6, 42.9, 33.7, 31.5, 26.1, 21.6 ppm. HRMS (APCI+, *m/z*): calculated for C₂₂H₂₇BrNO₂S [M+H⁺]: 448.0946, found: 448.0941.

(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-vinyloct-7-enyl)benzenesulfonamide (4e)




The title compound was prepared from **2** (0.50 mmol, 230 mg) following general procedure **A**. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.75) afforded **4e** (68% yield, 203 mg, 98% *ee*, [α]_D²⁰ = +32.6 (*c* 1.2 in CHCl₃)) as a colorless oil. Enantiomeric excess determined for Heck product **6e**. ¹H NMR (400 MHz, CDCl₃) δ 7.60-7.53 (m, 3H), 7.28-7.11 (m, 5H), 5.82-5.71 (m, 1H), 5.56-5.39 (m, 1H), 5.00-4.86 (m, 4H), 3.65 (m, 1H), 3.48 (m, 1H), 2.42 (m, 3H), 2.21 (m, minor peak, 1H), 1.99 (m, major peak + CH₂, 3H), 1.63 (m, major peak, 1H), 1.47 (m, minor peak, 1H), 1.33-1.11 (m, 5H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.4, 139.8, 139.7, 139.0, 138.3, 138.0, 136.7, 136.5, 134.1, 134.0, 133.7, 132.5, 129.6, 129.5, 129.4, 127.9, 127.8, 127.7, 127.6, 125.5, 124.7, 116.7, 116.4, 114.2, 55.6, 55.2, 43.6, 42.9, 33.6, 31.9, 31.8, 28.9, 28.8, 26.3, 26.2, 21.6 ppm. HRMS (APCI+, *m/z*): calculated for C₂₃H₂₉BrNO₂S [M+H]⁺: 462.1102, found: 462.1097.

General procedure B: Synthesis of compounds 5 and 6 by intramolecular Heck reaction



TBAB (1 g), TBAA (0.45 g, 1.5 mmol), Pd(OAc)₂ (3 mol%) and the corresponding AAA product (**3** or **4**) were stirred and heated at 100 °C for the indicated time (see Table 2). Water (3 mL) and EtOAc (3 mL) were added and, after cooling to r.t., the organic phase separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined organic phases were dried over MgSO₄ and concentrated under reduced pressure to yield the crude product which was purified by flash chromatography on silica gel, EtOAc/Pentane.


(+)-3-methyl-4-methylenechromene (5a)



The title compound was prepared from **3a** (0.29 mmol, 70 mg) following general procedure **B**. Reaction time: 15 min. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.4) afforded **5a** (93% yield, 43 mg, ratio exo:endo = 95:5, >99% *ee*, [α]_D²⁰ = +18.3 (*c* 0.6 in


(CHCl₃) as a colorless oil. Enantiomeric excess determined by chiral GC analysis, Chiraldex B-PM column (30 m x 0.25 mm), 5 min isothermic 50 °C then 2 °C/min gradient to 175 °C, retention times (min) 44.5 (major) and 44.9 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.57 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.20-7.14 (m, 1H), 6.93-6.85 (m, 1H), 6.84 (dd, *J* = 8.2 and 1.0 Hz, 1H), 5.50 (d, *J* = 0.7 Hz, 1H), 4.94 (d, *J* = 1.4 Hz, 1H), 4.19 (dd, *J* = 10.5 and 3.5 Hz, 1H), 3.91 (dd, *J* = 10.5 and 7.3 Hz, 1H), 2.73 (m, 1H), 1.20 (d, *J* = 6.9 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 154.1, 142.6, 129.3, 124.9, 121.3, 120.7, 117.1, 105.2, 71.8, 34.0, 15.6 ppm. HRMS (EI, *m/z*) calculated for C₁₁H₁₂O⁺: 160.0888, found: 160.0883.

(-)-3-ethyl-4-methylenechromene (5b)



The title compound was prepared from **3b** (0.27 mmol, 70 mg) following general procedure **B**. Reaction time: 15 min. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.5) afforded **5b** (96% yield, 45 mg, ratio exo:endo = 98:2, 98% *ee*, [α]_D²⁰ = -18.6 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral GC analysis, Chiraldex B-PM column (30 m x 0.25 mm), 5 min isothermic 50 °C then 2 °C/min gradient to 175 °C, retention times (min) 47.2 (minor) and 47.7 (major). ¹H NMR (400 MHz, CDCl₃) δ 7.56 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.19-7.15 (m, 1H), 6.92-6.88 (m, 1H), 6.83 (dd, *J* = 8.2 and 1.1 Hz, 1H), 5.52 (s, 1H), 4.89 (s, 1H), 4.20 (d, *J* = 3.1 Hz, 2H), 2.38 (m, 1H), 1.59 (m, 2H), 0.98 (t, *J* = 7.4 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 153.9, 140.8, 129.3, 125.0, 121.0, 120.6, 117.0, 107.0, 69.9, 42.2, 23.4, 11.8 ppm. HRMS (APCI+, *m/z*): calculated for C₁₂H₁₅O [M+H⁺]: 175.1123, found: 175.1118.


(+)-3-(but-3-enyl)-4-methylenechromene (5c)



The title compound was prepared from **3c** (0.25 mmol, 70 mg) following general procedure **B**. Reaction time: 1.5 h. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.7) afforded **5c** (84% yield, 42 mg, ratio exo:endo = >99:1, 96% *ee*, [α]_D²⁰ = +42.6 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral GC analysis, Chiraldex B-PM column (30 m x 0.25 mm), 5 min isothermic 50 °C then 2 °C/min gradient to 175 °C, retention times (min) 57.1 (minor) and 57.4 (major). ¹H NMR (400 MHz, CDCl₃) δ 7.56 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.19-7.15 (m, 1H), 6.92-6.88 (m, 1H), 6.83 (dd, *J* = 8.2 and 1.1 Hz, 1H), 5.87-5.76 (m, 1H), 5.52 (s, 1H), 5.06-4.97 (m, 2H), 4.89 (s, 1H), 4.20 (d, *J* = 2.9 Hz, 2H), 2.52 (m, 1H), 2.15 (m, 2H), 1.65 (m, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 153.8, 140.7, 138.3,


129.4, 125.1, 120.8, 120.7, 117.1, 115.0, 107.2, 70.1, 39.8, 31.2, 29.5 ppm. HRMS (APCI+, m/z): calculated for $C_{14}H_{17}O$ [$M+H^+$]: 201.1279, found: 201.1274.

(-)-4-methylene-3-(pent-4-enyl)chromene (5d)




The title compound was prepared from **3d** (0.81 mmol, 240 mg) following general procedure **B**. Reaction time: 1.5 h. Purification by column chromatography (SiO_2 , EtOAc/Pentane 1:99, R_f = 0.7) afforded **5d** (92% yield, 160 mg, ratio exo:endo = >99:1, 95% *ee*, $[\alpha]_D^{20}$ = -20.2 (*c* 0.4 in $CHCl_3$)) as a colorless oil. Enantiomeric excess determined for RCM product **9**. 1H NMR (400 MHz, $CDCl_3$) δ 7.56 (dd, J = 7.9 and 1.6 Hz, 1H), 7.20-7.15 (m, 1H), 6.92-6.88 (m, 1H), 6.84 (dd, J = 8.2 and 1.1 Hz, 1H), 5.86-5.76 (m, 1H), 5.51 (s, 1H), 5.03-4.93 (m, 2H), 4.89 (s, 1H), 4.19 (d, J = 3.0 Hz, 2H), 2.49 (m, 1H), 2.07 (m, 2H), 1.60-1.45 (m, 4H) ppm. ^{13}C NMR (101 MHz, $CDCl_3$) δ 153.9, 141.0, 138.6, 129.4, 125.1, 120.9, 120.7, 117.0, 114.6, 106.9, 70.1, 40.4, 33.7, 29.9, 26.6 ppm. HRMS (APCI+, m/z): calculated for $C_{15}H_{19}O$ [$M+H^+$]: 215.1436, found: 215.1430.

(-)-3-(hex-5-enyl)-4-methylenechromene (5e)




The title compound was prepared from **3e** (0.32 mmol, 100 mg) following general procedure **B**. Reaction time: 1.5 h. Purification by column chromatography (SiO_2 , EtOAc/Pentane 1:99, R_f = 0.7) afforded **5e** (89% yield, 65 mg, ratio exo:endo = >99:1, 99% *ee*, $[\alpha]_D^{20}$ = -27.0 (*c* 1.0 in $CHCl_3$)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OJ (99.8 % *n*-heptane/0.2% *i*-PrOH), 40 °C, retention times (min) 9.9 (minor) and 10.1 (major). 1H NMR (400 MHz, $CDCl_3$) δ 7.55 (dd, J = 7.9 and 1.6 Hz, 1H), 7.19-7.14 (m, 1H), 6.91-6.87 (m, 1H), 6.83 (dd, J = 8.2 and 1.1 Hz, 1H), 5.85-5.74 (m, 1H), 5.50 (s, 1H), 5.00-4.92 (m, 2H), 4.88 (s, 1H), 4.18 (d, J = 3.0 Hz, 2H), 2.47 (m, 1H), 2.05 (m, 2H), 1.54 (m, 2H), 1.40 (m, 4H) ppm. ^{13}C NMR (101 MHz, $CDCl_3$) δ 153.9, 141.1, 138.9, 129.3, 125.1, 121.0, 120.7, 117.0, 114.3, 106.8, 70.1, 40.5, 33.7, 30.2, 28.8, 26.7 ppm. HRMS (APCI+, m/z): calculated for $C_{16}H_{21}O$ [$M+H^+$]: 229.1592, found: 229.1587.

(+)-3-methyl-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6a)




The title compound was prepared from **4a** (0.24 mmol, 95 mg) following general procedure **B**. Reaction time: 15 min. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.4) afforded **6a** (92% yield, 68 mg, ratio *exo:endo* = 95:5, 99% *ee*, [α]_D²⁰ = 2.8 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralpak AD (99.5 % *n*-heptane/0.5% *i*-PrOH), 40 °C, retention times (min) 23.3 (major) and 30.2 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 8.4 Hz, 1H), 7.55-7.51 (m, 3H), 7.26-7.17 (m, 3H), 7.11-7.07 (m, 1H), 5.40 (d, *J* = 1.7 Hz, 1H), 4.86 (d, *J* = 1.8 Hz, 1H), 4.12 (dd, *J* = 13.3 and 4.9 Hz, 1H), 3.30 (dd, *J* = 13.3 and 10.4 Hz, 1H), 2.52 (m, 1H), 2.37 (s, 3H), 1.10 (d, *J* = 6.8 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.8, 143.6, 137.1, 136.2, 129.6, 128.4, 128.3, 127.0, 125.0, 124.9, 123.6, 108.6, 52.5, 33.3, 21.5, 17.6 ppm. HRMS (APCI+, *m/z*): calculated for C₁₈H₁₉NNaO₂S [M+H⁺]: 336.1034, found: 336.1029.

(-)-3-ethyl-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6b)




The title compound was prepared from **4b** (0.21 mmol, 86 mg) following general procedure **B**. Reaction time: 15 min. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.6) afforded **6b** (93% yield, 63 mg, ratio *exo:endo* = 98:2, 99% *ee*, [α]_D²⁰ = -26.6 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OJ-H (99 % *n*-heptane/1% *i*-PrOH), 40 °C, retention times (min) 33.3 (major) and 41.4 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (dd, *J* = 8.3 and 0.9 Hz, 1H), 7.57-7.55 (m, 2H), 7.49 (dd, *J* = 7.9 and 1.5 Hz, 1H), 7.20-7.18 (m, 3H), 7.07 (m, 1H), 5.33 (s, 1H), 4.79 (d, *J* = 1.1 Hz, 1H), 4.01 (dd, *J* = 13.1 and 4.7 Hz, 1H), 3.65 (dd, *J* = 13.1 and 8.0 Hz, 1H), 2.42-2.40 (m, 1H), 2.37 (s, 3H), 1.59-1.40 (m, 2H), 0.92 (t, *J* = 7.4 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.6, 142.5, 137.0, 136.2, 129.6, 128.4, 128.3, 127.1, 125.3, 124.7, 122.7, 109.6, 50.5, 41.1, 25.2, 21.5, 11.3 ppm. HRMS (APCI+, *m/z*): calculated for C₁₉H₂₂NO₂S [M+H⁺]: 328.1371, found: 328.1372.

(-)-3-(but-3-enyl)-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6c)




The title compound was prepared from **4c** (0.28 mmol, 120 mg) following general procedure **B**. Reaction time: 1 h. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.7) afforded **6c** (87% yield, 86 mg, ratio exo:endo = 98:2, 97% *ee*, [α]_D²⁰ = -7.2 (*c* 0.7 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OJ-H (99 % *n*-heptane/1% *i*-PrOH), 40 °C, retention times (min) 36.1 (major) and 41.0 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (dd, *J* = 8.4 and 0.9 Hz, 1H), 7.59-7.56 (m, 2H), 7.49 (dd, *J* = 7.9 and 1.5 Hz, 1H), 7.21-7.19 (m, 3H), 7.07 (m, 1H), 5.82-5.72 (m, 1H), 5.34 (s, 1H), 5.06-4.98 (m, 2H), 4.81 (d, *J* = 1.0 Hz, 1H), 3.98 (dd, *J* = 13.1 and 4.6 Hz, 1H), 3.71 (dd, *J* = 13.1 and 7.5 Hz, 1H), 2.54 (m, 1H), 2.38 (s, 3H), 2.10 (m, 2H), 1.56 (m, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.6, 142.6, 137.9, 137.0, 136.1, 129.6, 128.4, 127.9, 127.1, 125.4, 124.6, 122.5, 115.2, 109.8, 50.6, 38.9, 31.4, 30.8, 21.5 ppm. HRMS (APCI+, *m/z*): calculated for C₂₁H₂₄NO₂S [M+H⁺]: 354.1528, found: 354.1522.

(-)-4-methylene-3-(pent-4-enyl)-1-tosyl-1,2,3,4-tetrahydroquinoline (6d)



The title compound was prepared from **4d** (0.42 mmol, 190 mg) following general procedure **B**. Reaction time: 1 h. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.7) afforded **6d** (86% yield, 133 mg, ratio exo:endo = 98:2, 97% *ee*, [α]_D²⁰ = -3.2 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OJ-H (99 % *n*-heptane/1% *i*-PrOH), 40 °C, retention times (min) 35.4 (major) and 40.6 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (dd, *J* = 8.3 and 0.9 Hz, 1H), 7.57-7.55 (m, 2H), 7.48 (dd, *J* = 7.9 and 1.5 Hz, 1H), 7.23-7.18 (m, 3H), 7.09-7.05 (m, 1H), 5.83-5.72 (m, 1H), 5.32 (s, 1H), 5.01-4.93 (m, 2H), 4.79 (d, *J* = 1.1 Hz, 1H), 4.00 (dd, *J* = 13.1 and 4.7 Hz, 1H), 3.65 (dd, *J* = 13.1 and 7.9 Hz, 1H), 2.49 (m, 1H), 2.37 (s, 3H), 2.03 (m, 2H), 1.52-1.37 (m, 4H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.6, 142.7, 138.4, 137.0, 136.1, 129.6, 128.4, 128.2, 127.1, 125.4, 124.7, 122.6, 114.7, 109.6, 50.8, 39.4, 33.6, 31.8, 26.0, 21.5 ppm. HRMS (APCI+, *m/z*): calculated for C₂₂H₂₅NNaO₂S [M+Na⁺]: 390.1504, found: 390.1498.


(+)-3-(hex-5-enyl)-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6e)



The title compound was prepared from **4e** (0.29 mmol, 135 mg) following general procedure **B**. Reaction time: 1 h. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.8) afforded **6e** (77% yield, 85 mg, ratio exo:endo = 97:3, 98% *ee*, [α]_D²⁰ = +7.6 (*c* 1.2 in


CHCl₃) as a white waxy solid. Enantiomeric excess determined by chiral HPLC analysis, Chiralcel OJ-H (99 % *n*-heptane/1% *i*-PrOH), 40 °C, retention times (min) 29.5 (major) and 33.1 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (dd, *J* = 8.3 and 0.9 Hz, 1H), 7.57-7.55 (m, 2H), 7.48 (dd, *J* = 7.9 and 1.5 Hz, 1H), 7.23-7.18 (m, 3H), 7.09-7.05 (m, 1H), 5.84-5.74 (m, 1H), 5.32 (s, 1H), 5.01-4.93 (m, 2H), 4.79 (d, *J* = 1.1 Hz, 1H), 3.99 (dd, *J* = 13.1 and 4.7 Hz, 1H), 3.64 (dd, *J* = 13.1 and 7.9 Hz, 1H), 2.47 (m, 1H), 2.37 (s, 3H), 2.03 (m, 2H), 1.56-1.26 (m, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.6, 142.8, 138.7, 137.0, 136.1, 129.6, 128.4, 128.2, 127.1, 125.4, 124.7, 122.7, 114.4, 109.4, 50.8, 39.5, 33.6, 32.2, 28.8, 26.2, 21.5 ppm. HRMS (APCI+, *m/z*): calculated for C₂₃H₂₇NNaO₂S [M+Na⁺]: 404.1660, found: 404.1655.

General procedure C: RCM of compounds **5c**, **6c** and **5d**




The corresponding diene was dissolved in degassed toluene (2-10 mM) under a N₂ atmosphere. Hoveyda-Grubbs 2nd generation catalyst (5 mol%) was tipped into the solution and then the stirred solution was heated for 6 h at 80 °C. The mixture was cooled down to room temperature and the solvent was removed under reduced pressure to yield the crude product which was purified by flash chromatography on silica gel, EtOAc/Pentane.

(+)-2,3,3a,4-tetrahydrocyclopenta[*c*]chromene (**7**)




The title compound was prepared from **5c** (0.13 mmol, 25 mg) in toluene (15 mL) following general procedure C. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.7) afforded **7** (84% yield, 18 mg, 96% *ee*, [α]_D²⁰ = +19.6 (*c* 1.1 in CHCl₃)) as a colorless oil. Volatile compound under vacuum pressure. Enantiomeric excess determined by chiral GC analysis, Chiraldex B-PM column (30 m x 0.25 mm), 5 min isothermic 50 °C then 2 °C/min gradient to 175 °C, retention times (min) 57.9 (major) and 58.4 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.48 (dd, *J* = 7.6 and 1.5 Hz, 1H), 7.19-7.11 (m, 1H), 6.90-6.86 (m, 2H), 6.06 (m, 1H), 4.52 (dd, *J* = 10.1 and 5.1 Hz, 1H), 3.67 (dd, *J* = 12.0 and 10.1 Hz, 1H), 3.10 (m, 1H), 2.54-2.49 (m, 2H), 2.24-2.17 (m, 1H), 1.49-1.39 (m, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 153.9, 136.9, 128.8, 125.1, 121.0, 120.7, 119.8, 117.1, 72.4, 41.9, 31.8, 27.5 ppm. HRMS (APCI+, *m/z*): calculated for C₁₂H₁₃O [M+H⁺]: 173.0966, found: 173.0961.

(+)-5-tosyl-3,3a,4,5-tetrahydro-2H-cyclopenta[c]quinoline (8)




The title compound was prepared from **6c** (0.17 mmol, 60 mg) in toluene (15 mL) following general procedure C. Purification by column chromatography (SiO₂, EtOAc/Pentane 10:90, *R_f* = 0.7) afforded **8** (90% yield, 50 mg, 97% *ee*, [α]_D²⁰ = +59.6 (*c* 1.4 in CHCl₃)) as a white waxy solid. Enantiomeric excess determined by chiral HPLC analysis, Chiralpak AD-H (99 % *n*-heptane/1% *i*-PrOH), 40 °C, retention times (min) 50.4 (major) and 52.8 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 8.3 Hz, 1H), 7.54-7.52 (m, 3H), 7.22-7.18 (m, 3H), 7.12-7.08 (m, 1H), 6.10 (m, 1H), 4.58 (dd, *J* = 13.4 and 4.8 Hz, 1H), 2.99 (dd, *J* = 12.9 and 12.9 Hz, 1H), 2.51 (m, 1H), 2.37 (s, 3H), 2.36 (m, 1H), 2.09 (m, 1H), 1.38-1.26 (m, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 143.5, 138.2, 137.3, 135.0, 129.6, 127.7, 127.0, 125.2, 125.0, 124.8, 124.7, 124.4, 52.0, 40.6, 31.5, 29.4, 21.5 ppm. HRMS (APCI+, *m/z*): calculated for C₁₉H₂₀NO₂S [M+H⁺]: 326.1215, found: 326.1210.

(+)-6a,7,8,9-tetrahydro-6H-benzo[c]chromene (9)




The title compound was prepared from **5d** (0.26 mmol, 55 mg) in toluene (26 mL) following general procedure C. Purification by column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.7) afforded **9** (95% yield, 46 mg, 95% *ee*, [α]_D²⁰ = +124.8 (*c* 1.0 in CHCl₃)) as a colorless oil. Enantiomeric excess determined by chiral GC analysis, Chiraldex B-PM column (30 m x 0.25 mm), 5 min isothermic 50 °C then 2 °C/min gradient to 175 °C, retention times (min) 66.2 (major) and 67.0 (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.49 (dd, *J* = 7.9 and 1.6 Hz, 1H), 7.13-7.09 (m, 1H), 6.90-6.86 (m, 1H), 6.83 (dd, *J* = 8.2 and 1.1 Hz, 1H), 6.25 (m, 1H), 4.28 (dd, *J* = 10.4 and 4.6 Hz, 1H), 3.66 (dd, *J* = 12.0 and 10.4 Hz, 1H), 2.67 (m, 1H), 2.27 (m, 2H), 1.89 (m, 2H), 1.64 (m, 1H), 1.13 (m, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 154.1, 131.0, 128.2, 123.6, 121.7, 120.6, 118.6, 117.2, 71.3, 33.7, 25.9, 24.8, 21.4 ppm. HRMS (APCI+, *m/z*): calculated for C₁₃H₁₅O [M+H⁺]: 187.1123, found: 187.1121.

Stereoselective hydroboration-oxidation




((+)-3-methylchroman-4-yl)methanol (**10**)




In an oven dried Schlenk tube equipped with septum and stirring bar under a N₂ atmosphere, chromene **5a** (0.28 mmol, 45 mg) was dissolved in anhydrous THF (0.5 mL), cooled to 0 °C and 9-BBN-THF (0.5M solution in THF, 0.42 mmol, 840 μL) was then added dropwise. The reaction mixture was stirred for 3 h, then it was allowed to reach rt, after which sequentially EtOH (2.5 mL), aq. NaOH (1M, 2.5 mL) and aq H₂O₂ (30%, 2.0 mL) were added. The resulting mixture was stirred overnight at rt and then quenched with aq Na₂S₂O₃ (10%, 10 mL). CH₂Cl₂ (20 mL) was added, the layers were separated and the aqueous layer was extracted with CH₂Cl₂ (20 mL). The combined organic layers were dried and concentrated *in vacuo*. Flash column chromatography (SiO₂, EtOAc/Pentane 3:7, *R_f* = 0.6) afforded **10** (81% yield, 40 mg, [α]_D²⁰ = +79.0 (*c* 1.3 in CHCl₃)) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.18-7.12 (m, 2H), 6.89-6.82 (m, 2H), 4.12-4.02 (m, 2H), 3.97-3.88 (m, 2H), 2.93 (m, 1H), 2.39-2.29 (m, 1H), 1.10 (d, *J* = 7.1 Hz, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 154.7, 129.3, 128.0, 122.4, 120.2, 116.8, 69.7, 63.7, 40.7, 29.2, 13.0 ppm. HRMS (APCI+, *m/z*): calculated for C₁₁H₁₅O₂ [M+H⁺]: 179.1072, found: 179.1067.

Stereoselective hydrogenation




((+)-3-hexyl-4-methylchroman (**11**)



To an oven-dried flask was added RhCl(PPh₃)₃ (20 mg, 0.02 mmol) and a solution of **5e** (20 mg, 0.09 mmol) in benzene (2 mL). The flask was connected to a hydrogen balloon. After five vacuum/H₂-filling cycles, the reaction mixture was stirred at rt for 15 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (SiO₂, EtOAc/Pentane 1:99, *R_f* = 0.7) afforded **11a** (96% yield, 20 mg, 9:1 d.r., [α]_D²⁰ = +47.2 (*c* 1.0 in CHCl₃)) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.14-7.07 (m, 2H), 6.89-6.77 (m, 2H), 4.17 (dd, *J* = 11.0 and 2.7 Hz, 1H, minor (*anti*)), 4.07 (ddd, *J* = 10.8, 3.6 and 1.2 Hz, 1H, major (*syn*)), 3.92 (dd, *J* = 10.6 and 10.6 Hz, 1H), 2.92 (m, 1H, major (*syn*)),

2.62 (m, 1H, minor (*anti*)), 2.07 (m, 1H), 1.43-1.24 (m, 10H), 1.17 (d, $J = 7.2$ Hz, 3H, major (*syn*)), 0.9 (d, 3H, minor (*anti*)), 0.9 (t, $J = 6.6$ Hz, 3H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 153.9, 129.5, 128.2, 127.2, 120.0, 116.4, 66.2, 35.7, 32.3, 31.8, 29.5, 27.6, 26.9, 22.7, 17.4, 14.1 ppm. HRMS (APCI+, m/z): calculated for $\text{C}_{16}\text{H}_{25}\text{O}$ [$\text{M}+\text{H}^+$]: 233.1905, found: 233.1900.



(+)-4-methyl-3-pentyl-1-tosyl-1,2,3,4-tetrahydroquinoline (12)





Compound prepared from **6d** (60 mg, 0.16 mmol) in benzene (2 mL) and $\text{RhCl}(\text{PPh}_3)_3$ (38 mg, 0.040 mmol) following the procedure described for **11a**. Purification by flash column chromatography (SiO_2 , EtOAc/Pentane 10:90, $R_f = 0.7$) afforded **12** (98% yield, 58 mg, 10:1 d.r., $[\alpha]_D^{20} = +62.0$ (c 1.1 in CHCl_3)) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J = 8.3$ Hz, 1H), 7.50 (m, 2H), 7.20-7.14 (m, 3H), 7.03-7.01 (m, 2H), 4.13 (dd, $J = 13.6$ and 4.1 Hz, 1H, minor (*anti*)), 3.97 (ddd, $J = 12.7$, 4.2 and 0.9 Hz, 1H, major (*syn*)), 3.24 (dd, $J = 12.1$, 12.1 Hz, 1H, major (*syn*)), 3.15 (dd, $J = 13.6$, 10.2 Hz, 1H, minor (*anti*)), 2.64 (m, 1H), 2.35 (s, 3H), 1.65 (m, 1H), 1.32-1.19 (m, 8H), 0.88 (t, $J = 7.1$ Hz, 3H), 0.87 (d, 3H, $J = 6.9$ Hz, minor (*anti*)), 0.72 (d, $J = 7.2$ Hz, 3H, major (*syn*)) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 143.5, 135.9, 135.7, 135.5, 129.5, 128.9, 127.1, 126.6, 124.1, 122.9, 47.3, 35.5, 35.0, 31.8, 29.9, 26.6, 22.5, 21.5, 15.8, 14.0 ppm. HRMS (APCI+, m/z): calculated for $\text{C}_{22}\text{H}_{30}\text{NO}_2\text{S}$ [$\text{M}+\text{H}^+$]: 372.1997, found: 372.1992.

NMR spectra



(*E*)-2-(4-Bromobut-2-enyloxy)-1-bromobenzene (1)





(E)-N-(4-Bromobut-2-enyl)-N-(2-bromophenyl)-4-methylbenzenesulfonamide (2)





(+)-1-Bromo-2-(2methylbut-3-enyloxy)benzene (3a)





(+)-1-bromo-2-(2-ethylbut-3-enyloxy)benzene (3b)





(+)-1-bromo-2-(2-vinylhex-5-enyloxy)benzene (3c)





(+)-1-bromo-2-(2-vinylhept-6-enyloxy)benzene (3d)





(+)-1-bromo-2-(2-vinyloct-7-enyloxy)benzene (3e)





(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-methylbut-3-enyl)benzenesulfonamide (**4a**)





(+)-*N*-(2-bromophenyl)-*N*-(2-ethylbut-3-enyl)-4-methylbenzenesulfonamide (4b)





(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-vinylhex-5-enyl)benzenesulfonamide (**4c**)





(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-vinylhept-6-enyl)benzenesulfonamide (4d)





(+)-*N*-(2-bromophenyl)-4-methyl-*N*-(2-vinyloct-7-enyl)benzenesulfonamide (**4e**)





(+)-3-methyl-4-methylenechromene (5a)





(-)-3-ethyl-4-methylenechromene (5b)





(+)-3-(but-3-enyl)-4-methylenechromene (5c)





(-)-4-methylene-3-(pent-4-enyl)chromene (5d)





(-)-3-(hex-5-enyl)-4-methylenechromene (5e)





(+)-3-methyl-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6a)





(-)-3-ethyl-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6b)





(-)-3-(but-3-enyl)-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6c)





(-)-4-methylene-3-(pent-4-enyl)-1-tosyl-1,2,3,4-tetrahydroquinoline (6d)





(+)-3-(hex-5-enyl)-4-methylene-1-tosyl-1,2,3,4-tetrahydroquinoline (6e)





(+)-2,3,3a,4-tetrahydrocyclopenta[c]chromene (7)





(+)-5-tosyl-3,3a,4,5-tetrahydro-2H-cyclopenta[c]quinoline (8)





(+)-6a,7,8,9-tetrahydro-6H-benzo[c]chromene (9)





((+)-3-methylchroman-4-yl)methanol (10)



(+)-3-hexyl-4-methylchromane (11)




(+)-4-methyl-3-pentyl-1-tosyl-1,2,3,4-tetrahydroquinoline (12)



Selected IR spectra

Chromene 5e



Tetrahydroquinoline 6c

